Amicus’s path to unseat Sanofi in rare disease gets steeper after Phase 3 miss February 12, 2021 Auto Bot BioPharma, biopharma nl, New Jersey, Pharma, Pompe disease, rare disease 0 Amicus Therapeutics CEO John Crowley said the totality of data support the Pompe disease therapy’s submission to the FDA. That rolling application is on track for completion in the second quarter.